Compare Aurora Cannabis Inc (ACB) vs Braze Inc (BRZE) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Braze (BRZE) trades at $26.54, up 3.23% with bullish technical signals from moving averages. The company shows strong revenue growth trajectory from $238M in 2022 to $593M in 2025, though profitability remains elusive with a -15.51% net margin. Recent Q1 2027 earnings met expectations at $0.10 per share, while analyst sentiment remains overwhelmingly positive with 24 buy ratings and a $34.78 consensus target representing 31% upside potential.

The investment case hinges on Braze's accelerating revenue growth and market leadership in customer engagement software, offset by persistent losses and insider selling. While technical indicators support near-term momentum, execution on profitability remains the key catalyst for sustained upside. Risks include competitive pressures and the company's ability to convert growth into sustainable earnings.